Literature DB >> 12622903

[Research on the relationship between pathological features of the uveal melanoma and prognosis].

Linjie Guo1, Zhongyao Wu, Sheng Zhang, Jiaqi Chen, Siming Ai, Huling Zheng.   

Abstract

OBJECTIVE: To study the pathological features of uveal melanoma and to evaluate their influence on patients' prognosis.
METHODS: Paraffin embedded uveal melanoma tissues of 115 cases were examined using routine pathologic methods. Three histological types were classified according to the modified Callender system and patients were followed clinically. The data were done regression and survival analysis by SPSS statistic soft.
RESULTS: The patient with epithelial cell type, mixed type, and spindle cell type uveal melanoma have different life times, the average life time is 35.6 +/- 21.5 months, 63.7 +/- 37.0 months, 69.5 +/- 36.5 months in turn, patients with epithelial uveal melanoma had shorter survival time than other two types. The survival time was negatively related to the largest diameter of contact area with the sclera, the largest height and the depth of tumor invasion to the sclera.
CONCLUSIONS: Epithelial uveal melanoma is more malignant than the other two types. Histological classification of this tumor combined with other pathologic features can indicate the patient's prognosis.

Entities:  

Mesh:

Year:  2002        PMID: 12622903

Source DB:  PubMed          Journal:  Zhonghua Bing Li Xue Za Zhi        ISSN: 0529-5807


  2 in total

1.  Expression of connexin 43 and E-cadherin in choroidal melanoma.

Authors:  Ying-Ying Mou; Gui-Qiu Zhao; Jin-Yong Lin; Jie Zhao; Hong Lin; Li-Ting Hu; Qiang Xu; Qing Wang; Wei-Rong Sun
Journal:  Int J Ophthalmol       Date:  2011-04-18       Impact factor: 1.779

2.  Circulating MicroRNAs as Quantitative Biomarkers for Diagnosis and Prognosis of Uveal Melanoma.

Authors:  Wen-Da Zhou; Lei Shao; Li Dong; Rui-Heng Zhang; Yi-Fan Li; He-Yan Li; Hao-Tian Wu; Xu-Han Shi; Wen-Bin Wei
Journal:  Front Oncol       Date:  2022-03-31       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.